CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Ceribell Q3 loss misses estimates; raises 2026 revenue guidance

By Reuters News


Overview

  • US neurological diagnostics firm's Q3 revenue rose 30% yr/yr, slightly beating analyst expectations

  • Q3 loss per share widened and missed analyst expectations

  • Growth driven by record new customer additions and higher utilization


Outlook

  • Ceribell raises 2026 revenue guidance to $115 mln-$117 mln

  • Company says 2026 outlook excludes material contributions from neonate, pediatric and delirium products

  • Ceribell says delirium launch and upcoming hardware platform position company for pivotal 2027


Result Drivers

  • SAME-STORE GROWTH - Co said revenue growth was driven by higher utilization within existing accounts and increased adoption of its system

  • COST REDUCTIONS - Co said higher gross margin was due to manufacturing cost reduction initiatives and a new manufacturing line in Vietnam

  • HIGHER OPERATING EXPENSES - Commercial, R&D, stock-compensation and legal investments increased operating expenses 36% to $46.9 mln


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$29.30 mln

$29.16 mln (8 Analysts)

Q3 Loss Per Share

Miss

$0.55

$0.51 (8 Analysts)

Q3 Net Loss

Miss

$21.40 mln

$19.72 mln (7 Analysts)

Q3 Gross Profit

$26.30 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for CeriBell, Inc. is $30.00, about 11.3% above its November 2 closing price of $26.96


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.